Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
KLK13 downregulation occurs in tumour tissues in comparison with adjacent normal tissues from patients with oesophageal squamous cell carcinoma (OSCC).
KLK13 mRNA
levels were tested in OSCC tumour tissues and adjacent noncancerous tissues from 138 patients. In addition, the correlation between
KLK13 mRNA
levels and OSCC clinicopathologic features was analysed.
KLK13 mRNA
levels decreased notably in tumour tissues compared with those in adjacent noncancerous tissues. And decreased
KLK13 mRNA
levels indicated significant correlations with higher tumour grade, elevated TNM (UICC, 2009) stage classification, deeper infiltration and more lymph node
metastases
. And thus KLK13 may be a promising diagnostic marker. Decreased
KLK13 mRNA
levels also correlate with poor survival, which indicates that
KLK13 mRNA
expression may be a potential prognostic marker, although it could not be an independent prognostic factor by multivariate analysis. In vitro experiments of the OSCC cell lines KYSE150 and KYSE450 demonstrated that overexpression of KLK13 inhibits cell invasion and migration. Thus, KLK13 is a unique novel molecule useful for monitoring OSCC progression. Full elucidation of the role of KLK13 in OSCC may reveal avenues for investigating the molecule's functional potential as a novel therapeutic drug for targeting OSCC.
...
PMID:Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma. 2922 24